View Future GrowthCH Biotech R&D 過去の業績過去 基準チェック /36CH Biotech R&Dは、平均年間8.1%の収益成長を遂げていますが、 Chemicals業界の収益は、年間 減少しています。収益は、平均年間1.7% 12.1%収益成長率で 成長しています。 CH Biotech R&Dの自己資本利益率は18.4%であり、純利益率は26.8%です。主要情報8.10%収益成長率7.05%EPS成長率Chemicals 業界の成長7.89%収益成長率12.12%株主資本利益率18.35%ネット・マージン26.77%前回の決算情報31 Mar 2026最近の業績更新Reported Earnings • May 19First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: NT$869.5m (up 1.9% from 1Q 2025). Net income: NT$426.7m (up 6.8% from 1Q 2025). Profit margin: 49% (up from 47% in 1Q 2025). The increase in margin was primarily driven by lower expenses.Reported Earnings • Mar 12Full year 2025 earnings released: EPS: NT$4.51 (vs NT$4.63 in FY 2024)Full year 2025 results: EPS: NT$4.51 (down from NT$4.63 in FY 2024). Revenue: NT$1.82b (up 11% from FY 2024). Net income: NT$464.0m (down 2.6% from FY 2024). Profit margin: 26% (down from 29% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.Reported Earnings • Nov 08Third quarter 2025 earnings released: NT$0.16 loss per share (vs NT$0.90 loss in 3Q 2024)Third quarter 2025 results: NT$0.16 loss per share (improved from NT$0.90 loss in 3Q 2024). Revenue: NT$216.7m (up 61% from 3Q 2024). Net loss: NT$16.9m (loss narrowed 82% from 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 22% per year, which means it is well ahead of earnings.Reported Earnings • Aug 08Second quarter 2025 earnings released: EPS: NT$0.37 (vs NT$1.27 in 2Q 2024)Second quarter 2025 results: EPS: NT$0.37 (down from NT$1.27 in 2Q 2024). Revenue: NT$420.5m (up 4.9% from 2Q 2024). Net income: NT$37.7m (down 71% from 2Q 2024). Profit margin: 9.0% (down from 33% in 2Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.Reported Earnings • May 07First quarter 2025 earnings released: EPS: NT$3.89 (vs NT$4.08 in 1Q 2024)First quarter 2025 results: EPS: NT$3.89 (down from NT$4.08 in 1Q 2024). Revenue: NT$853.7m (up 3.5% from 1Q 2024). Net income: NT$399.4m (down 4.7% from 1Q 2024). Profit margin: 47% (down from 51% in 1Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.お知らせ • Apr 25CH Biotech R&D Co., Ltd. to Report Q1, 2025 Results on May 06, 2025CH Biotech R&D Co., Ltd. announced that they will report Q1, 2025 results on May 06, 2025すべての更新を表示Recent updatesReported Earnings • May 19First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: NT$869.5m (up 1.9% from 1Q 2025). Net income: NT$426.7m (up 6.8% from 1Q 2025). Profit margin: 49% (up from 47% in 1Q 2025). The increase in margin was primarily driven by lower expenses.Reported Earnings • Mar 12Full year 2025 earnings released: EPS: NT$4.51 (vs NT$4.63 in FY 2024)Full year 2025 results: EPS: NT$4.51 (down from NT$4.63 in FY 2024). Revenue: NT$1.82b (up 11% from FY 2024). Net income: NT$464.0m (down 2.6% from FY 2024). Profit margin: 26% (down from 29% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.Declared Dividend • Mar 12Final dividend of NT$4.30 announcedShareholders will receive a dividend of NT$4.30. Ex-date: 26th March 2026 Payment date: 16th April 2026 Dividend yield will be 5.8%, which is higher than the industry average of 4.0%. Sustainability & Growth Dividend is not adequately covered by earnings (96% earnings payout ratio) nor is it covered by cash flows (264% cash payout ratio). The dividend has increased by an average of 7.5% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 6.6% to bring the payout ratio under control, which is less than the 33% EPS growth achieved over the last 5 years.お知らせ • Mar 05CH Biotech R&D Co., Ltd., Annual General Meeting, May 26, 2026CH Biotech R&D Co., Ltd., Annual General Meeting, May 26, 2026, at 09:00 Taipei Standard Time. Location: no,89, wen hsien rd., nantou city, nantou county TaiwanReported Earnings • Nov 08Third quarter 2025 earnings released: NT$0.16 loss per share (vs NT$0.90 loss in 3Q 2024)Third quarter 2025 results: NT$0.16 loss per share (improved from NT$0.90 loss in 3Q 2024). Revenue: NT$216.7m (up 61% from 3Q 2024). Net loss: NT$16.9m (loss narrowed 82% from 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 22% per year, which means it is well ahead of earnings.New Risk • Sep 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 116% Cash payout ratio: 263% Minor Risk Share price has been volatile over the past 3 months (6.5% average weekly change).Valuation Update With 7 Day Price Move • Aug 21Investor sentiment improves as stock rises 22%After last week's 22% share price gain to NT$117, the stock trades at a trailing P/E ratio of 32.9x. Average trailing P/E is 26x in the Chemicals industry in Taiwan. Total returns to shareholders of 80% over the past three years.Reported Earnings • Aug 08Second quarter 2025 earnings released: EPS: NT$0.37 (vs NT$1.27 in 2Q 2024)Second quarter 2025 results: EPS: NT$0.37 (down from NT$1.27 in 2Q 2024). Revenue: NT$420.5m (up 4.9% from 2Q 2024). Net income: NT$37.7m (down 71% from 2Q 2024). Profit margin: 9.0% (down from 33% in 2Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.Declared Dividend • Aug 07Dividend of NT$0.50 announcedShareholders will receive a dividend of NT$0.50. Ex-date: 21st August 2025 Payment date: 19th September 2025 Dividend yield will be 4.5%, which is higher than the industry average of 4.0%. Sustainability & Growth Dividend is not adequately covered by earnings (92% earnings payout ratio) nor is it covered by cash flows (135% cash payout ratio). The dividend has increased by an average of 8.3% per year over the past 9 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 2.5% to bring the payout ratio under control, which is less than the 28% EPS growth achieved over the last 5 years.Valuation Update With 7 Day Price Move • Jul 31Investor sentiment improves as stock rises 17%After last week's 17% share price gain to NT$95.10, the stock trades at a trailing P/E ratio of 21.4x. Average trailing P/E is 20x in the Chemicals industry in Taiwan. Total returns to shareholders of 47% over the past three years.Reported Earnings • May 07First quarter 2025 earnings released: EPS: NT$3.89 (vs NT$4.08 in 1Q 2024)First quarter 2025 results: EPS: NT$3.89 (down from NT$4.08 in 1Q 2024). Revenue: NT$853.7m (up 3.5% from 1Q 2024). Net income: NT$399.4m (down 4.7% from 1Q 2024). Profit margin: 47% (down from 51% in 1Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.お知らせ • Apr 25CH Biotech R&D Co., Ltd. to Report Q1, 2025 Results on May 06, 2025CH Biotech R&D Co., Ltd. announced that they will report Q1, 2025 results on May 06, 2025Upcoming Dividend • Mar 14Upcoming dividend of NT$3.60 per shareEligible shareholders must have bought the stock before 20 March 2025. Payment date: 23 April 2025. Payout ratio is on the higher end at 88% but the company is not cash flow positive. Trailing yield: 4.9%. Within top quartile of Taiwanese dividend payers (4.5%). Higher than average of industry peers (2.7%).分析記事 • Mar 10Solid Earnings May Not Tell The Whole Story For CH Biotech R&D (TWSE:6534)The recent earnings posted by CH Biotech R&D Co., Ltd. ( TWSE:6534 ) were solid, but the stock didn't move as much as...New Risk • Mar 05New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 22% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 96% Paying a dividend despite having no free cash flows. High level of non-cash earnings (22% accrual ratio).Declared Dividend • Feb 27Dividend of NT$3.60 announcedShareholders will receive a dividend of NT$3.60. Ex-date: 20th March 2025 Payment date: 23rd April 2025 Dividend yield will be 4.8%, which is higher than the industry average of 4.0%. Sustainability & Growth Dividend is not adequately covered by earnings (96% earnings payout ratio) and the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 6.8% per year over the past 9 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 6.3% to bring the payout ratio under control, which is less than the 9.9% EPS growth achieved over the last 5 years.お知らせ • Feb 26CH Biotech R&D Co., Ltd., Annual General Meeting, May 20, 2025CH Biotech R&D Co., Ltd., Annual General Meeting, May 20, 2025, at 09:00 Taipei Standard Time. Location: no,89, wen hsien rd., nantou city, nantou county Taiwanお知らせ • Feb 15CH Biotech R&D Co., Ltd. to Report Q4, 2024 Results on Feb 25, 2025CH Biotech R&D Co., Ltd. announced that they will report Q4, 2024 results on Feb 25, 2025Reported Earnings • Nov 07Third quarter 2024 earnings released: NT$0.89 loss per share (vs NT$0.45 loss in 3Q 2023)Third quarter 2024 results: NT$0.89 loss per share (further deteriorated from NT$0.45 loss in 3Q 2023). Revenue: NT$134.8m (up 22% from 3Q 2023). Net loss: NT$92.0m (loss widened 111% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 18% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Oct 25CH Biotech R&D Co., Ltd. to Report Q3, 2024 Results on Nov 05, 2024CH Biotech R&D Co., Ltd. announced that they will report Q3, 2024 results on Nov 05, 2024Upcoming Dividend • Aug 16Upcoming dividend of NT$0.50 per shareEligible shareholders must have bought the stock before 23 August 2024. Payment date: 19 September 2024. Payout ratio is on the higher end at 95%, and the cash payout ratio is above 100%. Trailing yield: 5.3%. Within top quartile of Taiwanese dividend payers (4.4%). Higher than average of industry peers (2.4%).Reported Earnings • Aug 13Second quarter 2024 earnings released: EPS: NT$1.27 (vs NT$1.96 in 2Q 2023)Second quarter 2024 results: EPS: NT$1.27 (down from NT$1.96 in 2Q 2023). Revenue: NT$400.7m (down 13% from 2Q 2023). Net income: NT$130.1m (down 32% from 2Q 2023). Profit margin: 33% (down from 41% in 2Q 2023). Over the last 3 years on average, earnings per share has increased by 16% per year and the company’s share price has also increased by 16% per year.お知らせ • Jul 30CH Biotech R&D Co., Ltd. to Report Q2, 2024 Results on Aug 06, 2024CH Biotech R&D Co., Ltd. announced that they will report Q2, 2024 results at 9:00 AM, Taipei Standard Time on Aug 06, 2024Buy Or Sell Opportunity • Jul 26Now 20% overvaluedThe stock has been flat over the last 90 days, currently trading at NT$82.60. The fair value is estimated to be NT$68.59, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 20% over the last 3 years. Earnings per share has grown by 27%.Reported Earnings • May 09First quarter 2024 earnings released: EPS: NT$4.08 (vs NT$4.05 in 1Q 2023)First quarter 2024 results: EPS: NT$4.08 (up from NT$4.05 in 1Q 2023). Revenue: NT$824.8m (up 3.0% from 1Q 2023). Net income: NT$419.1m (up 6.7% from 1Q 2023). Profit margin: 51% (up from 49% in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 27% per year whereas the company’s share price has increased by 23% per year.お知らせ • Apr 28CH Biotech R&D Co., Ltd. to Report Q1, 2024 Results on May 07, 2024CH Biotech R&D Co., Ltd. announced that they will report Q1, 2024 results on May 07, 2024Upcoming Dividend • Mar 14Upcoming dividend of NT$3.09 per shareEligible shareholders must have bought the stock before 21 March 2024. Payment date: 12 April 2024. Payout ratio and cash payout ratio are on the higher end at 86% and 87% respectively. Trailing yield: 4.5%. Lower than top quartile of Taiwanese dividend payers (4.8%). In line with average of industry peers (4.1%).Reported Earnings • Mar 03Full year 2023 earnings released: EPS: NT$4.76 (vs NT$4.79 in FY 2022)Full year 2023 results: EPS: NT$4.76 (down from NT$4.79 in FY 2022). Revenue: NT$1.51b (up 5.6% from FY 2022). Net income: NT$463.3m (flat on FY 2022). Profit margin: 31% (down from 33% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has only increased by 30% per year, which means it is significantly lagging earnings growth.Declared Dividend • Feb 29Dividend of NT$3.09 announcedShareholders will receive a dividend of NT$3.09. Ex-date: 21st March 2024 Payment date: 12th April 2024 Dividend yield will be 4.3%, which is higher than the industry average of 4.0%. Sustainability & Growth Dividend is not covered by earnings (110% earnings payout ratio). However, it is well covered by cash flows (44% cash payout ratio). The dividend has increased over the past 8 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 22% to bring the payout ratio under control, which is more than the 6.4% EPS growth achieved over the last 5 years.お知らせ • Feb 28+ 1 more updateCH Biotech R&D Co., Ltd. Approves Cash Dividend for the Second Half of 2023, Payable on April 12, 2024CH Biotech R&D Co., Ltd. approved cash dividend of TWD 3.09 per share for the second half of 2023. Total amount of cash dividends to shareholders TWD 317,652,000. Ex-rights (ex-dividend) record date of March 27, 2024. Payment date of common stock cash dividend distribution of April 12, 2024.New Risk • Feb 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 7.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.4% average weekly change). Minor Risks Dividend is not well covered by earnings (110% payout ratio). Shareholders have been diluted in the past year (5.9% increase in shares outstanding).Valuation Update With 7 Day Price Move • Dec 22Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to NT$82.40, the stock trades at a trailing P/E ratio of 19.7x. Average forward P/E is 21x in the Chemicals industry in Taiwan. Total returns to shareholders of 96% over the past three years.New Risk • Dec 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 5.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (5.5% average weekly change). Shareholders have been diluted in the past year (5.9% increase in shares outstanding).Valuation Update With 7 Day Price Move • Nov 22Investor sentiment improves as stock rises 18%After last week's 18% share price gain to NT$94.60, the stock trades at a trailing P/E ratio of 22.6x. Average trailing P/E is 21x in the Chemicals industry in Taiwan. Total returns to shareholders of 112% over the past three years.Reported Earnings • Nov 14Third quarter 2023 earnings released: NT$0.45 loss per share (vs NT$0.30 loss in 3Q 2022)Third quarter 2023 results: NT$0.45 loss per share (further deteriorated from NT$0.30 loss in 3Q 2022). Revenue: NT$110.9m (up 20% from 3Q 2022). Net loss: NT$43.6m (loss widened 51% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth.New Risk • Oct 28New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by earnings (107% payout ratio). Shareholders have been diluted in the past year (5.9% increase in shares outstanding).Upcoming Dividend • Sep 19Upcoming dividend of NT$1.00 per share at 2.6% yieldEligible shareholders must have bought the stock before 26 September 2023. Payment date: 18 October 2023. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 2.6%. Lower than top quartile of Taiwanese dividend payers (5.4%). Lower than average of industry peers (3.7%).Reported Earnings • Aug 12Second quarter 2023 earnings released: EPS: NT$1.96 (vs NT$3.44 in 2Q 2022)Second quarter 2023 results: EPS: NT$1.96 (down from NT$3.44 in 2Q 2022). Revenue: NT$459.3m (down 34% from 2Q 2022). Net income: NT$190.0m (down 43% from 2Q 2022). Profit margin: 41% (down from 48% in 2Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.お知らせ • Aug 09CH Biotech R&D Co., Ltd. Approves Cash Dividend for the First Half Ended June 30, 2023CH Biotech R&D Co., Ltd. announced its Board of Directors approved appropriations of earnings in cash dividends to shareholders of TWD 1 per share for the first half ended June 30, 2023. Total amount of cash dividends to shareholders is TWD 97,083,000.Reported Earnings • Mar 22Full year 2022 earnings released: EPS: NT$4.79 (vs NT$3.00 in FY 2021)Full year 2022 results: EPS: NT$4.79 (up from NT$3.00 in FY 2021). Revenue: NT$1.43b (up 41% from FY 2021). Net income: NT$465.4m (up 60% from FY 2021). Profit margin: 33% (up from 29% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has only increased by 20% per year, which means it is significantly lagging earnings growth.Upcoming Dividend • Mar 07Upcoming dividend of NT$3.88 per share at 4.7% yieldEligible shareholders must have bought the stock before 14 March 2023. Payment date: 10 April 2023. Payout ratio is a comfortable 20% and this is well supported by cash flows. Trailing yield: 4.7%. Lower than top quartile of Taiwanese dividend payers (6.1%). Lower than average of industry peers (7.5%).Valuation Update With 7 Day Price Move • Jan 03Investor sentiment improved over the past weekAfter last week's 15% share price gain to NT$79.00, the stock trades at a trailing P/E ratio of 11.9x. Average trailing P/E is 14x in the Chemicals industry in Taiwan. Total returns to shareholders of 39% over the past three years.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Yong-Xiang Chiu was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Oct 13Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to NT$57.30, the stock trades at a trailing P/E ratio of 8.6x. Average trailing P/E is 12x in the Chemicals industry in Taiwan. Total loss to shareholders of 19% over the past three years.Reported Earnings • Aug 19First half 2022 earnings released: EPS: NT$6.22 (vs NT$2.56 in 1H 2021)First half 2022 results: EPS: NT$6.22 (up from NT$2.56 in 1H 2021). Revenue: NT$1.29b (up 92% from 1H 2021). Net income: NT$603.4m (up 143% from 1H 2021). Profit margin: 47% (up from 37% in 1H 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Yong-Xiang Chiu was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Apr 11Investor sentiment improved over the past weekAfter last week's 30% share price gain to NT$98.80, the stock trades at a trailing P/E ratio of 28.6x. Average trailing P/E is 18x in the Chemicals industry in Taiwan. Negligible returns to shareholders over past three years.Valuation Update With 7 Day Price Move • Mar 14Investor sentiment improved over the past weekAfter last week's 21% share price gain to NT$85.50, the stock trades at a trailing P/E ratio of 24.8x. Average trailing P/E is 17x in the Chemicals industry in Taiwan. Total loss to shareholders of 25% over the past three years.Upcoming Dividend • Mar 07Upcoming dividend of NT$1.50 per shareEligible shareholders must have bought the stock before 14 March 2022. Payment date: 31 March 2022. Payout ratio is a comfortable 43% and this is well supported by cash flows. Trailing yield: 2.1%. Lower than top quartile of Taiwanese dividend payers (5.2%). Lower than average of industry peers (2.8%).Reported Earnings • Mar 05Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: NT$3.45 (up from NT$1.19 in FY 2020). Revenue: NT$1.02b (up 45% from FY 2020). Net income: NT$291.5m (up 191% from FY 2020). Profit margin: 29% (up from 14% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 12% per year whereas the company’s share price has fallen by 15% per year.Valuation Update With 7 Day Price Move • Feb 24Investor sentiment improved over the past weekAfter last week's 16% share price gain to NT$75.30, the stock trades at a trailing P/E ratio of 37.5x. Average trailing P/E is 21x in the Chemicals industry in Taiwan. Total loss to shareholders of 26% over the past three years.お知らせ • Feb 18CH Biotech R&D Co., Ltd., Annual General Meeting, Jun 08, 2022CH Biotech R&D Co., Ltd., Annual General Meeting, Jun 08, 2022.Valuation Update With 7 Day Price Move • Sep 09Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to NT$54.50, the stock trades at a trailing P/E ratio of 27.1x. Average trailing P/E is 15x in the Chemicals industry in Taiwan. Total loss to shareholders of 38% over the past three years.Reported Earnings • Aug 18First half 2021 earnings released: EPS NT$2.94 (vs NT$2.12 in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: NT$671.5m (up 19% from 1H 2020). Net income: NT$248.1m (up 39% from 1H 2020). Profit margin: 37% (up from 32% in 1H 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.Valuation Update With 7 Day Price Move • Jul 19Investor sentiment improved over the past weekAfter last week's 27% share price gain to NT$63.00, the stock trades at a trailing P/E ratio of 53.1x. Average trailing P/E is 17x in the Chemicals industry in Taiwan. Total loss to shareholders of 33% over the past three years.Upcoming Dividend • Jun 16Upcoming dividend of NT$0.50 per shareEligible shareholders must have bought the stock before 22 June 2021. Payment date: 09 July 2021. Trailing yield: 0.9%. Lower than top quartile of Taiwanese dividend payers (5.0%). Lower than average of industry peers (2.8%).Valuation Update With 7 Day Price Move • Apr 25Investor sentiment improved over the past weekAfter last week's 15% share price gain to NT$57.50, the stock trades at a trailing P/E ratio of 48.5x. Average trailing P/E is 21x in the Chemicals industry in Taiwan. Total loss to shareholders of 40% over the past three years.分析記事 • Apr 05CH Biotech R&D (GTSM:6534) Takes On Some Risk With Its Use Of DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Reported Earnings • Apr 01Full year 2020 earnings released: EPS NT$1.19 (vs NT$2.26 in FY 2019)The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: NT$702.2m (down 17% from FY 2019). Net income: NT$100.2m (down 47% from FY 2019). Profit margin: 14% (down from 23% in FY 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has only fallen by 22% per year, which means it has not declined as severely as earnings.分析記事 • Mar 18A Look At CH Biotech R&D's (GTSM:6534) Share Price ReturnsWe think intelligent long term investing is the way to go. But along the way some stocks are going to perform badly...お知らせ • Feb 24CH Biotech R&D Co., Ltd., Annual General Meeting, May 28, 2021CH Biotech R&D Co., Ltd., Annual General Meeting, May 28, 2021.Is New 90 Day High Low • Feb 18New 90-day low: NT$50.00The company is down 15% from its price of NT$58.80 on 20 November 2020. The Taiwanese market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 5.0% over the same period.分析記事 • Feb 09Are CH Biotech R&D Co., Ltd.'s (GTSM:6534) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?It is hard to get excited after looking at CH Biotech R&D's (GTSM:6534) recent performance, when its stock has declined...分析記事 • Jan 11Returns On Capital At CH Biotech R&D (GTSM:6534) Paint An Interesting PictureWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? Amongst...Is New 90 Day High Low • Dec 23New 90-day low: NT$52.10The company is down 13% from its price of NT$59.90 on 25 September 2020. The Taiwanese market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 14% over the same period.分析記事 • Dec 15Does CH Biotech R&D (GTSM:6534) Have A Healthy Balance Sheet?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Nov 24Tread With Caution Around CH Biotech R&D Co., Ltd.'s (GTSM:6534) 1.8% Dividend YieldDividend paying stocks like CH Biotech R&D Co., Ltd. (GTSM:6534) tend to be popular with investors, and for good...収支内訳CH Biotech R&D の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史TWSE:6534 収益、費用、利益 ( )TWD Millions日付収益収益G+A経費研究開発費31 Mar 261,83549147441031 Dec 251,81946449740730 Sep 251,76643951038830 Jun 251,68436450337131 Mar 251,66545748836831 Dec 241,63647645936330 Sep 241,50438142035030 Jun 241,48043040433731 Mar 241,53949039332431 Dec 231,51546338930530 Sep 231,42543038329730 Jun 231,40744537328531 Mar 231,64458938328331 Dec 221,43446535127230 Sep 221,59361932826530 Jun 221,63564732223531 Mar 221,27443729022331 Dec 211,01929126722130 Sep 2187520825621730 Jun 2181017025321331 Mar 2175613525220331 Dec 2070210025219330 Sep 206797925018630 Jun 206565724917931 Mar 2074812426317131 Dec 1984119027716230 Sep 1987622428015230 Jun 1991225828314231 Mar 1989627226712831 Dec 1888028525111430 Sep 1886129423610430 Jun 188413032209531 Mar 187642582168731 Dec 177812902008130 Sep 178283301957830 Jun 178053191887531 Mar 177623071697431 Dec 166982581697130 Sep 166742381637430 Jun 166642521556931 Mar 166092281436631 Dec 155112051205630 Sep 15430199904030 Jun 154042096734質の高い収益: 6534は 高品質の収益 を持っています。利益率の向上: 6534の現在の純利益率 (26.8%)は、昨年(27.4%)よりも低くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: 6534の収益は過去 5 年間で年間8.1%増加しました。成長の加速: 6534の過去 1 年間の収益成長率 ( 7.6% ) は、5 年間の平均 ( 年間8.1%を下回っています。収益対業界: 6534の過去 1 年間の収益成長率 ( 7.6% ) はChemicals業界-7.2%を上回りました。株主資本利益率高いROE: 6534の 自己資本利益率 ( 18.4% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YMaterials 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 14:31終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋CH Biotech R&D Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Yenya KuoCapital Securities CorporationHsiu Chi LinMasterlink Securities Investment Advisory
Reported Earnings • May 19First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: NT$869.5m (up 1.9% from 1Q 2025). Net income: NT$426.7m (up 6.8% from 1Q 2025). Profit margin: 49% (up from 47% in 1Q 2025). The increase in margin was primarily driven by lower expenses.
Reported Earnings • Mar 12Full year 2025 earnings released: EPS: NT$4.51 (vs NT$4.63 in FY 2024)Full year 2025 results: EPS: NT$4.51 (down from NT$4.63 in FY 2024). Revenue: NT$1.82b (up 11% from FY 2024). Net income: NT$464.0m (down 2.6% from FY 2024). Profit margin: 26% (down from 29% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.
Reported Earnings • Nov 08Third quarter 2025 earnings released: NT$0.16 loss per share (vs NT$0.90 loss in 3Q 2024)Third quarter 2025 results: NT$0.16 loss per share (improved from NT$0.90 loss in 3Q 2024). Revenue: NT$216.7m (up 61% from 3Q 2024). Net loss: NT$16.9m (loss narrowed 82% from 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 22% per year, which means it is well ahead of earnings.
Reported Earnings • Aug 08Second quarter 2025 earnings released: EPS: NT$0.37 (vs NT$1.27 in 2Q 2024)Second quarter 2025 results: EPS: NT$0.37 (down from NT$1.27 in 2Q 2024). Revenue: NT$420.5m (up 4.9% from 2Q 2024). Net income: NT$37.7m (down 71% from 2Q 2024). Profit margin: 9.0% (down from 33% in 2Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.
Reported Earnings • May 07First quarter 2025 earnings released: EPS: NT$3.89 (vs NT$4.08 in 1Q 2024)First quarter 2025 results: EPS: NT$3.89 (down from NT$4.08 in 1Q 2024). Revenue: NT$853.7m (up 3.5% from 1Q 2024). Net income: NT$399.4m (down 4.7% from 1Q 2024). Profit margin: 47% (down from 51% in 1Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.
お知らせ • Apr 25CH Biotech R&D Co., Ltd. to Report Q1, 2025 Results on May 06, 2025CH Biotech R&D Co., Ltd. announced that they will report Q1, 2025 results on May 06, 2025
Reported Earnings • May 19First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: NT$869.5m (up 1.9% from 1Q 2025). Net income: NT$426.7m (up 6.8% from 1Q 2025). Profit margin: 49% (up from 47% in 1Q 2025). The increase in margin was primarily driven by lower expenses.
Reported Earnings • Mar 12Full year 2025 earnings released: EPS: NT$4.51 (vs NT$4.63 in FY 2024)Full year 2025 results: EPS: NT$4.51 (down from NT$4.63 in FY 2024). Revenue: NT$1.82b (up 11% from FY 2024). Net income: NT$464.0m (down 2.6% from FY 2024). Profit margin: 26% (down from 29% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.
Declared Dividend • Mar 12Final dividend of NT$4.30 announcedShareholders will receive a dividend of NT$4.30. Ex-date: 26th March 2026 Payment date: 16th April 2026 Dividend yield will be 5.8%, which is higher than the industry average of 4.0%. Sustainability & Growth Dividend is not adequately covered by earnings (96% earnings payout ratio) nor is it covered by cash flows (264% cash payout ratio). The dividend has increased by an average of 7.5% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 6.6% to bring the payout ratio under control, which is less than the 33% EPS growth achieved over the last 5 years.
お知らせ • Mar 05CH Biotech R&D Co., Ltd., Annual General Meeting, May 26, 2026CH Biotech R&D Co., Ltd., Annual General Meeting, May 26, 2026, at 09:00 Taipei Standard Time. Location: no,89, wen hsien rd., nantou city, nantou county Taiwan
Reported Earnings • Nov 08Third quarter 2025 earnings released: NT$0.16 loss per share (vs NT$0.90 loss in 3Q 2024)Third quarter 2025 results: NT$0.16 loss per share (improved from NT$0.90 loss in 3Q 2024). Revenue: NT$216.7m (up 61% from 3Q 2024). Net loss: NT$16.9m (loss narrowed 82% from 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 22% per year, which means it is well ahead of earnings.
New Risk • Sep 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 116% Cash payout ratio: 263% Minor Risk Share price has been volatile over the past 3 months (6.5% average weekly change).
Valuation Update With 7 Day Price Move • Aug 21Investor sentiment improves as stock rises 22%After last week's 22% share price gain to NT$117, the stock trades at a trailing P/E ratio of 32.9x. Average trailing P/E is 26x in the Chemicals industry in Taiwan. Total returns to shareholders of 80% over the past three years.
Reported Earnings • Aug 08Second quarter 2025 earnings released: EPS: NT$0.37 (vs NT$1.27 in 2Q 2024)Second quarter 2025 results: EPS: NT$0.37 (down from NT$1.27 in 2Q 2024). Revenue: NT$420.5m (up 4.9% from 2Q 2024). Net income: NT$37.7m (down 71% from 2Q 2024). Profit margin: 9.0% (down from 33% in 2Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.
Declared Dividend • Aug 07Dividend of NT$0.50 announcedShareholders will receive a dividend of NT$0.50. Ex-date: 21st August 2025 Payment date: 19th September 2025 Dividend yield will be 4.5%, which is higher than the industry average of 4.0%. Sustainability & Growth Dividend is not adequately covered by earnings (92% earnings payout ratio) nor is it covered by cash flows (135% cash payout ratio). The dividend has increased by an average of 8.3% per year over the past 9 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 2.5% to bring the payout ratio under control, which is less than the 28% EPS growth achieved over the last 5 years.
Valuation Update With 7 Day Price Move • Jul 31Investor sentiment improves as stock rises 17%After last week's 17% share price gain to NT$95.10, the stock trades at a trailing P/E ratio of 21.4x. Average trailing P/E is 20x in the Chemicals industry in Taiwan. Total returns to shareholders of 47% over the past three years.
Reported Earnings • May 07First quarter 2025 earnings released: EPS: NT$3.89 (vs NT$4.08 in 1Q 2024)First quarter 2025 results: EPS: NT$3.89 (down from NT$4.08 in 1Q 2024). Revenue: NT$853.7m (up 3.5% from 1Q 2024). Net income: NT$399.4m (down 4.7% from 1Q 2024). Profit margin: 47% (down from 51% in 1Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.
お知らせ • Apr 25CH Biotech R&D Co., Ltd. to Report Q1, 2025 Results on May 06, 2025CH Biotech R&D Co., Ltd. announced that they will report Q1, 2025 results on May 06, 2025
Upcoming Dividend • Mar 14Upcoming dividend of NT$3.60 per shareEligible shareholders must have bought the stock before 20 March 2025. Payment date: 23 April 2025. Payout ratio is on the higher end at 88% but the company is not cash flow positive. Trailing yield: 4.9%. Within top quartile of Taiwanese dividend payers (4.5%). Higher than average of industry peers (2.7%).
分析記事 • Mar 10Solid Earnings May Not Tell The Whole Story For CH Biotech R&D (TWSE:6534)The recent earnings posted by CH Biotech R&D Co., Ltd. ( TWSE:6534 ) were solid, but the stock didn't move as much as...
New Risk • Mar 05New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 22% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 96% Paying a dividend despite having no free cash flows. High level of non-cash earnings (22% accrual ratio).
Declared Dividend • Feb 27Dividend of NT$3.60 announcedShareholders will receive a dividend of NT$3.60. Ex-date: 20th March 2025 Payment date: 23rd April 2025 Dividend yield will be 4.8%, which is higher than the industry average of 4.0%. Sustainability & Growth Dividend is not adequately covered by earnings (96% earnings payout ratio) and the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 6.8% per year over the past 9 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 6.3% to bring the payout ratio under control, which is less than the 9.9% EPS growth achieved over the last 5 years.
お知らせ • Feb 26CH Biotech R&D Co., Ltd., Annual General Meeting, May 20, 2025CH Biotech R&D Co., Ltd., Annual General Meeting, May 20, 2025, at 09:00 Taipei Standard Time. Location: no,89, wen hsien rd., nantou city, nantou county Taiwan
お知らせ • Feb 15CH Biotech R&D Co., Ltd. to Report Q4, 2024 Results on Feb 25, 2025CH Biotech R&D Co., Ltd. announced that they will report Q4, 2024 results on Feb 25, 2025
Reported Earnings • Nov 07Third quarter 2024 earnings released: NT$0.89 loss per share (vs NT$0.45 loss in 3Q 2023)Third quarter 2024 results: NT$0.89 loss per share (further deteriorated from NT$0.45 loss in 3Q 2023). Revenue: NT$134.8m (up 22% from 3Q 2023). Net loss: NT$92.0m (loss widened 111% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 18% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Oct 25CH Biotech R&D Co., Ltd. to Report Q3, 2024 Results on Nov 05, 2024CH Biotech R&D Co., Ltd. announced that they will report Q3, 2024 results on Nov 05, 2024
Upcoming Dividend • Aug 16Upcoming dividend of NT$0.50 per shareEligible shareholders must have bought the stock before 23 August 2024. Payment date: 19 September 2024. Payout ratio is on the higher end at 95%, and the cash payout ratio is above 100%. Trailing yield: 5.3%. Within top quartile of Taiwanese dividend payers (4.4%). Higher than average of industry peers (2.4%).
Reported Earnings • Aug 13Second quarter 2024 earnings released: EPS: NT$1.27 (vs NT$1.96 in 2Q 2023)Second quarter 2024 results: EPS: NT$1.27 (down from NT$1.96 in 2Q 2023). Revenue: NT$400.7m (down 13% from 2Q 2023). Net income: NT$130.1m (down 32% from 2Q 2023). Profit margin: 33% (down from 41% in 2Q 2023). Over the last 3 years on average, earnings per share has increased by 16% per year and the company’s share price has also increased by 16% per year.
お知らせ • Jul 30CH Biotech R&D Co., Ltd. to Report Q2, 2024 Results on Aug 06, 2024CH Biotech R&D Co., Ltd. announced that they will report Q2, 2024 results at 9:00 AM, Taipei Standard Time on Aug 06, 2024
Buy Or Sell Opportunity • Jul 26Now 20% overvaluedThe stock has been flat over the last 90 days, currently trading at NT$82.60. The fair value is estimated to be NT$68.59, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 20% over the last 3 years. Earnings per share has grown by 27%.
Reported Earnings • May 09First quarter 2024 earnings released: EPS: NT$4.08 (vs NT$4.05 in 1Q 2023)First quarter 2024 results: EPS: NT$4.08 (up from NT$4.05 in 1Q 2023). Revenue: NT$824.8m (up 3.0% from 1Q 2023). Net income: NT$419.1m (up 6.7% from 1Q 2023). Profit margin: 51% (up from 49% in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 27% per year whereas the company’s share price has increased by 23% per year.
お知らせ • Apr 28CH Biotech R&D Co., Ltd. to Report Q1, 2024 Results on May 07, 2024CH Biotech R&D Co., Ltd. announced that they will report Q1, 2024 results on May 07, 2024
Upcoming Dividend • Mar 14Upcoming dividend of NT$3.09 per shareEligible shareholders must have bought the stock before 21 March 2024. Payment date: 12 April 2024. Payout ratio and cash payout ratio are on the higher end at 86% and 87% respectively. Trailing yield: 4.5%. Lower than top quartile of Taiwanese dividend payers (4.8%). In line with average of industry peers (4.1%).
Reported Earnings • Mar 03Full year 2023 earnings released: EPS: NT$4.76 (vs NT$4.79 in FY 2022)Full year 2023 results: EPS: NT$4.76 (down from NT$4.79 in FY 2022). Revenue: NT$1.51b (up 5.6% from FY 2022). Net income: NT$463.3m (flat on FY 2022). Profit margin: 31% (down from 33% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has only increased by 30% per year, which means it is significantly lagging earnings growth.
Declared Dividend • Feb 29Dividend of NT$3.09 announcedShareholders will receive a dividend of NT$3.09. Ex-date: 21st March 2024 Payment date: 12th April 2024 Dividend yield will be 4.3%, which is higher than the industry average of 4.0%. Sustainability & Growth Dividend is not covered by earnings (110% earnings payout ratio). However, it is well covered by cash flows (44% cash payout ratio). The dividend has increased over the past 8 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 22% to bring the payout ratio under control, which is more than the 6.4% EPS growth achieved over the last 5 years.
お知らせ • Feb 28+ 1 more updateCH Biotech R&D Co., Ltd. Approves Cash Dividend for the Second Half of 2023, Payable on April 12, 2024CH Biotech R&D Co., Ltd. approved cash dividend of TWD 3.09 per share for the second half of 2023. Total amount of cash dividends to shareholders TWD 317,652,000. Ex-rights (ex-dividend) record date of March 27, 2024. Payment date of common stock cash dividend distribution of April 12, 2024.
New Risk • Feb 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 7.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.4% average weekly change). Minor Risks Dividend is not well covered by earnings (110% payout ratio). Shareholders have been diluted in the past year (5.9% increase in shares outstanding).
Valuation Update With 7 Day Price Move • Dec 22Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to NT$82.40, the stock trades at a trailing P/E ratio of 19.7x. Average forward P/E is 21x in the Chemicals industry in Taiwan. Total returns to shareholders of 96% over the past three years.
New Risk • Dec 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 5.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (5.5% average weekly change). Shareholders have been diluted in the past year (5.9% increase in shares outstanding).
Valuation Update With 7 Day Price Move • Nov 22Investor sentiment improves as stock rises 18%After last week's 18% share price gain to NT$94.60, the stock trades at a trailing P/E ratio of 22.6x. Average trailing P/E is 21x in the Chemicals industry in Taiwan. Total returns to shareholders of 112% over the past three years.
Reported Earnings • Nov 14Third quarter 2023 earnings released: NT$0.45 loss per share (vs NT$0.30 loss in 3Q 2022)Third quarter 2023 results: NT$0.45 loss per share (further deteriorated from NT$0.30 loss in 3Q 2022). Revenue: NT$110.9m (up 20% from 3Q 2022). Net loss: NT$43.6m (loss widened 51% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth.
New Risk • Oct 28New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by earnings (107% payout ratio). Shareholders have been diluted in the past year (5.9% increase in shares outstanding).
Upcoming Dividend • Sep 19Upcoming dividend of NT$1.00 per share at 2.6% yieldEligible shareholders must have bought the stock before 26 September 2023. Payment date: 18 October 2023. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 2.6%. Lower than top quartile of Taiwanese dividend payers (5.4%). Lower than average of industry peers (3.7%).
Reported Earnings • Aug 12Second quarter 2023 earnings released: EPS: NT$1.96 (vs NT$3.44 in 2Q 2022)Second quarter 2023 results: EPS: NT$1.96 (down from NT$3.44 in 2Q 2022). Revenue: NT$459.3m (down 34% from 2Q 2022). Net income: NT$190.0m (down 43% from 2Q 2022). Profit margin: 41% (down from 48% in 2Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.
お知らせ • Aug 09CH Biotech R&D Co., Ltd. Approves Cash Dividend for the First Half Ended June 30, 2023CH Biotech R&D Co., Ltd. announced its Board of Directors approved appropriations of earnings in cash dividends to shareholders of TWD 1 per share for the first half ended June 30, 2023. Total amount of cash dividends to shareholders is TWD 97,083,000.
Reported Earnings • Mar 22Full year 2022 earnings released: EPS: NT$4.79 (vs NT$3.00 in FY 2021)Full year 2022 results: EPS: NT$4.79 (up from NT$3.00 in FY 2021). Revenue: NT$1.43b (up 41% from FY 2021). Net income: NT$465.4m (up 60% from FY 2021). Profit margin: 33% (up from 29% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has only increased by 20% per year, which means it is significantly lagging earnings growth.
Upcoming Dividend • Mar 07Upcoming dividend of NT$3.88 per share at 4.7% yieldEligible shareholders must have bought the stock before 14 March 2023. Payment date: 10 April 2023. Payout ratio is a comfortable 20% and this is well supported by cash flows. Trailing yield: 4.7%. Lower than top quartile of Taiwanese dividend payers (6.1%). Lower than average of industry peers (7.5%).
Valuation Update With 7 Day Price Move • Jan 03Investor sentiment improved over the past weekAfter last week's 15% share price gain to NT$79.00, the stock trades at a trailing P/E ratio of 11.9x. Average trailing P/E is 14x in the Chemicals industry in Taiwan. Total returns to shareholders of 39% over the past three years.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Yong-Xiang Chiu was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Oct 13Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to NT$57.30, the stock trades at a trailing P/E ratio of 8.6x. Average trailing P/E is 12x in the Chemicals industry in Taiwan. Total loss to shareholders of 19% over the past three years.
Reported Earnings • Aug 19First half 2022 earnings released: EPS: NT$6.22 (vs NT$2.56 in 1H 2021)First half 2022 results: EPS: NT$6.22 (up from NT$2.56 in 1H 2021). Revenue: NT$1.29b (up 92% from 1H 2021). Net income: NT$603.4m (up 143% from 1H 2021). Profit margin: 47% (up from 37% in 1H 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Yong-Xiang Chiu was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Apr 11Investor sentiment improved over the past weekAfter last week's 30% share price gain to NT$98.80, the stock trades at a trailing P/E ratio of 28.6x. Average trailing P/E is 18x in the Chemicals industry in Taiwan. Negligible returns to shareholders over past three years.
Valuation Update With 7 Day Price Move • Mar 14Investor sentiment improved over the past weekAfter last week's 21% share price gain to NT$85.50, the stock trades at a trailing P/E ratio of 24.8x. Average trailing P/E is 17x in the Chemicals industry in Taiwan. Total loss to shareholders of 25% over the past three years.
Upcoming Dividend • Mar 07Upcoming dividend of NT$1.50 per shareEligible shareholders must have bought the stock before 14 March 2022. Payment date: 31 March 2022. Payout ratio is a comfortable 43% and this is well supported by cash flows. Trailing yield: 2.1%. Lower than top quartile of Taiwanese dividend payers (5.2%). Lower than average of industry peers (2.8%).
Reported Earnings • Mar 05Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: NT$3.45 (up from NT$1.19 in FY 2020). Revenue: NT$1.02b (up 45% from FY 2020). Net income: NT$291.5m (up 191% from FY 2020). Profit margin: 29% (up from 14% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 12% per year whereas the company’s share price has fallen by 15% per year.
Valuation Update With 7 Day Price Move • Feb 24Investor sentiment improved over the past weekAfter last week's 16% share price gain to NT$75.30, the stock trades at a trailing P/E ratio of 37.5x. Average trailing P/E is 21x in the Chemicals industry in Taiwan. Total loss to shareholders of 26% over the past three years.
お知らせ • Feb 18CH Biotech R&D Co., Ltd., Annual General Meeting, Jun 08, 2022CH Biotech R&D Co., Ltd., Annual General Meeting, Jun 08, 2022.
Valuation Update With 7 Day Price Move • Sep 09Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to NT$54.50, the stock trades at a trailing P/E ratio of 27.1x. Average trailing P/E is 15x in the Chemicals industry in Taiwan. Total loss to shareholders of 38% over the past three years.
Reported Earnings • Aug 18First half 2021 earnings released: EPS NT$2.94 (vs NT$2.12 in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: NT$671.5m (up 19% from 1H 2020). Net income: NT$248.1m (up 39% from 1H 2020). Profit margin: 37% (up from 32% in 1H 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.
Valuation Update With 7 Day Price Move • Jul 19Investor sentiment improved over the past weekAfter last week's 27% share price gain to NT$63.00, the stock trades at a trailing P/E ratio of 53.1x. Average trailing P/E is 17x in the Chemicals industry in Taiwan. Total loss to shareholders of 33% over the past three years.
Upcoming Dividend • Jun 16Upcoming dividend of NT$0.50 per shareEligible shareholders must have bought the stock before 22 June 2021. Payment date: 09 July 2021. Trailing yield: 0.9%. Lower than top quartile of Taiwanese dividend payers (5.0%). Lower than average of industry peers (2.8%).
Valuation Update With 7 Day Price Move • Apr 25Investor sentiment improved over the past weekAfter last week's 15% share price gain to NT$57.50, the stock trades at a trailing P/E ratio of 48.5x. Average trailing P/E is 21x in the Chemicals industry in Taiwan. Total loss to shareholders of 40% over the past three years.
分析記事 • Apr 05CH Biotech R&D (GTSM:6534) Takes On Some Risk With Its Use Of DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Reported Earnings • Apr 01Full year 2020 earnings released: EPS NT$1.19 (vs NT$2.26 in FY 2019)The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: NT$702.2m (down 17% from FY 2019). Net income: NT$100.2m (down 47% from FY 2019). Profit margin: 14% (down from 23% in FY 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has only fallen by 22% per year, which means it has not declined as severely as earnings.
分析記事 • Mar 18A Look At CH Biotech R&D's (GTSM:6534) Share Price ReturnsWe think intelligent long term investing is the way to go. But along the way some stocks are going to perform badly...
お知らせ • Feb 24CH Biotech R&D Co., Ltd., Annual General Meeting, May 28, 2021CH Biotech R&D Co., Ltd., Annual General Meeting, May 28, 2021.
Is New 90 Day High Low • Feb 18New 90-day low: NT$50.00The company is down 15% from its price of NT$58.80 on 20 November 2020. The Taiwanese market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 5.0% over the same period.
分析記事 • Feb 09Are CH Biotech R&D Co., Ltd.'s (GTSM:6534) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?It is hard to get excited after looking at CH Biotech R&D's (GTSM:6534) recent performance, when its stock has declined...
分析記事 • Jan 11Returns On Capital At CH Biotech R&D (GTSM:6534) Paint An Interesting PictureWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? Amongst...
Is New 90 Day High Low • Dec 23New 90-day low: NT$52.10The company is down 13% from its price of NT$59.90 on 25 September 2020. The Taiwanese market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 14% over the same period.
分析記事 • Dec 15Does CH Biotech R&D (GTSM:6534) Have A Healthy Balance Sheet?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
分析記事 • Nov 24Tread With Caution Around CH Biotech R&D Co., Ltd.'s (GTSM:6534) 1.8% Dividend YieldDividend paying stocks like CH Biotech R&D Co., Ltd. (GTSM:6534) tend to be popular with investors, and for good...